Betrixaban

Betrixaban
Clinical data
Trade names	Bevyxxa
Other names	PRT054021, PRT064445
AHFS/Drugs.com	bevyxxa
Routes of; administration	By mouth
ATC code	B01AF04 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Protein binding	60%
Elimination half-life	19–27 hrs
Duration of action	≥72 hrs
Excretion	85% feces, 11% urine
Identifiers
	IUPAC name N-(5-Chloropyridin-2-yl)-2-([4-(N,N-dimethylcarbamimidoyl)benzoyl]amino)-5-methoxybenzamide;
CAS Number	330942-05-7 ;
PubChem CID	10275777;
DrugBank	DB12364 ;
ChemSpider	18981107 ;
UNII	74RWP7W0J9;
KEGG	D08873;
ChEBI	CHEBI:140421;
ChEMBL	ChEMBL512351 ;
CompTox Dashboard (EPA)	DTXSID10954727 ;
ECHA InfoCard	100.207.746
Chemical and physical data
Formula	C23H22ClN5O3
Molar mass	451.91 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl;
	InChI InChI=1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31) ; Key:XHOLNRLADUSQLD-UHFFFAOYSA-N ;
	(what is this?) (verify)

Betrixaban (trade name Bevyxxa) is an oral anticoagulant drug which acts as a direct factor Xa inhibitor. Betrixaban is FDA approved for venous thrombosis prevention in adults hospitalized for an acute illness who are at risk for thromboembolic complications. Compared to other directly acting oral anticoagulants betrixaban has relatively low renal excretion and is not metabolized by CYP3A4.